THANK YOU FOR SUBSCRIBING
A biotechnology company must streamline its data collection and analytic output to execute a successful digital strategy. Researchers can use this additional insight to improve R&D effectiveness and reduce costs by enhancing the efficiency of their research teams.
FREMONT, CA: In recent years, the biotechnology industry has encountered phenomenal growth. The biotechnology industry helped governments and markets develop vital vaccines and innovative treatments during the COVID-19 pandemic.
Transforming BioTech through Cutting-Edge Technology
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
Biotech companies have historically been sluggish to innovate with digital technologies such as artificial intelligence, the Internet of Things, and quantum computing. However, the effects of the COVID-19 pandemic have altered biotechnology companies' digital mindset.
In response to the rise of the telecommuting workforce and the increasing need for innovative medical therapies, investments in digital transformation have increased significantly.
Most BioTech leaders (76 percent) view digital innovation as a competitive differentiator. Companies wishing to remain competitive must move swiftly to stay up with other biotech firms. This is especially important for small to mid-sized biotech companies with limited resources.
What is Biotechnology's Digital Transformation?
Digital transformation in biotech incorporates digital technology into all aspects of a biotech company, optimizing operations and maximizing value delivery. A necessary component of a biotech's digital transformation is a cultural shift; biotechs must explicitly challenge the current market and innovate to differentiate.
Difficulties Facing the Biotechnology Industry
The biotechnology industry faces a unique set of challenges that are uncommon in other industries. Fortunately, properly implemented technological solutions can help mitigate or strengthen the response to these challenges.
Strict and Complex Regulatory Requirements: Governments worldwide have enacted complex regulations that biotech companies must adhere to to ensure the public's health and safety. Numerous governments have policies and regulatory agencies that must sanction new products and treatments.
High Cost of R&D: Biotechnology companies expend significant money to create, test, and gain approval for their products and treatments. A single drug's R&D expenses can easily exceed $1 billion. In addition to the exorbitant cost, the average R&D cycle (from concept to market release) is approximately 15 years. This renders biotech firms incapable of generating a return on investment for over a decade.
Consumer Price Pressures: Drug pricing is an economic and political combustible potato. This is notably true in countries without national healthcare systems, like the United States. Numerous governments have proposed additional restrictions on the pricing models of biotechnology companies. This would reduce profits. However, supply and demand may impact industry profits, as the life sciences industry experienced a 35 percent to 45 percent decline in revenue from 2015 to 2018.
Talent Shortages: The global pandemic boosted the demand for medical solutions the biotechnology industry provides. Globally, biotechnology companies needed help to recruit and retain top talent.
Negative Public Perceptions: Biotech companies rushed to provide the vaccines and medical remedies necessary during the COVID-19 pandemic, so the public has become increasingly wary of the industry's new technologies. During the pandemic, people received significant false or inconsistent information.
Increased Competition: Venture capitalists view the biotechnology industry as having enormous potential. The consensus is that the biotechnology industry has matured and is now less hazardous than it was previously. The result is a 45 percent increase in VC activity in 2021. In the same year, there were over one hundred biotech IPOs in the United States alone. Europe and China are rapidly gaining ground on the United States regarding biotech investment. Recent funding for biotechnology companies in Europe and China has increased by a factor of two and four, respectively.
More in News